Last Updated | 8 April 2026

ARAR2221

A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
External Registry
Site Status Queensland Children's Hospital John Hunter Children's Hospital Royal Children's Hospital Children's Hospital at Westmead Perth Children's Hospital Starship Children's Hospital Christchurch Hospital
Queensland Children's Hospital (QLD)
John Hunter Children's Hospital (NSW)
Sydney Children's Hospital (NSW)
Monash Health Clayton (VIC)
Royal Children's Hospital (VIC)
Women's and Children's Hospital (SA)
Perth Children's Hospital (WA)
Royal Hobart Hospital (TAS)
Children's Hospital at Westmead (NSW)
Starship Children's Hospital (NZ)
Christchurch Hospital (NZ)
Preparing to Open
Open
Temporarily Closed
Closed
Complete
Adult Sites These sites are not monitored. Status may vary.
Diagnosis Stage Newly diagnosed
National Sponsor Children's Oncology Group
Open Date N/A
Conditions Stage II Nasopharyngeal Carcinoma AJCC v8
Stage III Nasopharyngeal Carcinoma AJCC v8
Stage IV Nasopharyngeal Carcinoma AJCC v8
Patient Range <21 years
Disease Type Head and neck tumours
Study Type Interventional
International Sponsor N/A

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.